X0609 4 2026-11-02 0001275187 ANGIODYNAMICS INC ANGO 0002162813 Honroth Eric false 14 PLAZA DRIVE LATHAM NY 12110 true true false false President and CEO false Common Stock 2026-11-02 4 A false 62928 0 A 62928 D Common Stock 2026-11-02 4 A false 38265 0 A 101193 D Performance Right 2026-11-02 4 A false 62928 0 A Common Stock 62928 62928 D The acquisition of 62,928 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents 62,928 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments consistent with awards granted to other executive officers of the Company and beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued employment through each applicable vesting date. The acquisition of 38,265 shares of Common Stock represents 38,265 restricted stock units granted to replace equity compensation the Reporting Person forfeited at his prior employer, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in two equal annual installments, such that 50% of the restricted stock units will vest on each of November 2, 2027 and November 2, 2028, subject to the Reporting Person's continued employment through each vesting date. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned, if at all, based on a combination of the Company's revenue, adjusted EBITDA, and total shareholder return ("TSR") relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement to the extent relative TSR over the three-year performance period exceeds the 75th percentile or is below the 25th percentile (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. /s/ Lawrence T. Weiss, as Attorney in Fact 2026-11-04